NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he discussed the company's mission to revolutionize antiviral treatment through its nanoviricide platform and highlighted progress of lead drug candidate NV-387. During the interview, Dr. Diwan explained how nanoviricides are designed to prevent viral escape, function independently of patient immune status, and offer broad-spectrum potential across patient populations, from infants to geriatrics.
He noted that NV-387 has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles, and has completed a Phase I clinical trial with no reported adverse events. Dr. Diwan added that a Phase II clinical trial for NV-387 targeting MPox is ready to begin in the Democratic Republic of Congo following regulatory clearance, positioning the candidate as a potential empirical therapy for acute respiratory and other viral infections with an estimated market opportunity exceeding $17 billion by 2030.
The interview underscores the significance of NanoViricides' platform technology, which aims to overcome common limitations of antiviral drugs, such as viral resistance and dependence on patient immune status. The nanoviricide approach involves encapsulating antiviral agents in a biomimetic viral envelope that mimics the target virus, allowing for precise binding and neutralization. This design could enable broad-spectrum activity, potentially addressing unmet medical needs in viral outbreaks where no specific treatment exists.
NV-387's progress is particularly noteworthy given its safety profile and efficacy across multiple virus families. The upcoming Phase II trial for MPox represents a critical step toward clinical validation. The company's pipeline also includes candidates for other viral diseases, including herpes, influenza, HIV, and hepatitis C, as detailed in the press release.
Investors and stakeholders can access the full interview and additional updates via the company's newsroom at https://ibn.fm/NNVC.
